Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Susquehanna Maintains Negative on Intel, Raises Price Target to $24

Susquehanna analyst Christopher Rolland maintains Intel (NASDAQ:INTC) with a Negative and raises the price target from $22 to $24.
byBenzinga Newsdesk
January 23, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Susquehanna analyst Christopher Rolland maintains Intel (NASDAQ:INTC) with a Negative and raises the price target from $22 to $24.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Jazz Pharmaceuticals Analysis Reveals THC And CBD Therapy Alleviates MS Spasticity

By Nicolas Jose Rodriguez
May 25, 11:15 PM
Treatment with the cannabis-based oral spray Nabiximols has been found to significantly relieve spasticity, a common symptom of multiple sclerosis (MS), according to a new analysis of two MS clinical trials. Spasticity is characterized by increased muscle stiffness and spasms, which can be uncomfortable and hinder movement.

JAZZ

Read More

Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More

By Lara Goldstein
May 31, 11:59 AM
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics committee and the Clinical Trials Registry to begin the world's first Phase 2a take-home LSD microdosing trial in patients with Major Depressive Disorder (MDD).

CMPS